Home › Research › Health systems and care delivery
Advancing Early Detection of Alzheimer Disease in the Primary Care Setting in the United States
Mielke Michelle M, Kurzman H Ricky, Hu Yan Helen, Cho Min, Liss Jonathan, Burns Jeffrey M, Obisesan Thomas O, Hornbecker Michael et al.. Neurology. Clinical practice, 2025-12-25
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
As evidence supporting the robustness of blood-based biomarker (BBM) testing for Alzheimer disease (AD) continues to emerge, understanding the perceptions, drivers, and barriers to the adoption of these tests among primary care physicians (PCPs) in the United States is crucial for improving patient outcomes and advancing clinical management of AD. In this study, we perform a survey of PCPs in the United States to better understand current practices for detecting and diagnosing mild cognitive impairment (MCI) or mild dementia due to AD and to identify drivers and barriers to adopting BBM testing in primary care clinics in the United States. This was a cross-sectional study involving a self-administered quantitative online survey. An advisory board was convened before and after the survey to advise on the survey design and discuss survey results. The survey was conducted online in the United States between December 2023 and January 2024, excluding Vermont and Maine because of state laws restricting PCP participation in market research. A total of 603 PCPs from the United States completed the survey for their self-reported perception and adoption of BBM tests for early diagnosis of AD, including awareness and/or experience with testing for patients with suspected cognitive/memory issues, and their belief, motivation, and obstacles for ordering BBM tests. Lack of effective diagnostic tools in the primary care setting and recognition of MCI/early AD symptoms were among the top barriers to early diagnosis of MCI/mild dementia due to AD. Although PCPs manage or treat patients with MCI/mild dementia independently, awareness and adoption of AD BBM tests are substantially lower ( 65%). Despite practice and perception barriers, two-thirds of PCPs reported that they would order a BBM test for patients with cognitive concerns to improve the diagnosis and management of AD. However, concerns were raised regarding testing accuracy, financial burden, and reimbursement. Primary care physicians are willing to adopt blood-based biomarker tests for diagnosing MCI and mild dementia due to AD, provided that they receive enhanced education, clear guidelines, and reimbursement support.
What this study adds
Evidence grade: Low
This is a cross-sectional study of 603 participants. This survey of U.S. primary care physicians examined practices and barriers around blood-based biomarker testing for early detection of Alzheimer's disease. It reports on diagnosis and adoption of testing, not on treating, curing, or preventing the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Mielke Michelle, M., Ricky, K. H., Helen, H. Y., Min, C., Jonathan, L., Burns Jeffrey, M., et al. (2026). Advancing Early Detection of Alzheimer Disease in the Primary Care Setting in the United States. Neurology. Clinical practice. https://doi.org/10.1212/cpj.0000000000200568
Vancouver
Mielke Michelle M, Ricky KH, Helen HY, Min C, Jonathan L, Burns Jeffrey M, et al. Advancing Early Detection of Alzheimer Disease in the Primary Care Setting in the United States. Neurology. Clinical practice. 2026. doi:10.1212/cpj.0000000000200568. PMID: 41445935.
BibTeX
@article{mielkemichelle2026-41445935,
author = {Mielke Michelle, M. and Ricky, Kurzman H and Helen, Hu Yan and Min, Cho and Jonathan, Liss and Burns Jeffrey, M. and Obisesan Thomas, O. and Michael, Hornbecker and others},
title = {{Advancing Early Detection of Alzheimer Disease in the Primary Care Setting in the United States}},
journal = {Neurology. Clinical practice},
year = {2026},
doi = {10.1212/cpj.0000000000200568},
pmid = {41445935},
url = {https://doi.org/10.1212/cpj.0000000000200568}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- An advisory board was convened before and after the survey to advise on the survey design and discuss survey results.
Why it matters
This survey of U.S. primary care physicians examined practices and barriers around blood-based biomarker testing for early detection of Alzheimer's disease. It reports on diagnosis and adoption of testing, not on treating, curing, or preventing the disease.
Study details
- Study designcross-sectional
- Participants603
- Evidence strengthLow
How this study scored 51/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurology. Clinical practice) |
| Journal's citation record | 0 / 4 | Neurology Clinical Practice: journal h-index 60 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 603 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 7 times (OpenAlex, 2026-10-17) |
| Citations per year | 2 / 5 | 3.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 4.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Harald Juergen Hampel: h-index 136 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Emory University: institution h-index 1,367 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 9 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41445935) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Health systems and care delivery from nearby years
Also in Health systems and care delivery
172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.